[18F]AlF-NOTA-LM3 PET/CT在高分化神经内分泌肿瘤患者中的诊断效能与临床意义评估
前瞻性随机对照研究纳入78例组织学确诊的高分化神经内分泌肿瘤患者,A组38例比较[18F]AlF-NOTA-LM3与[68Ga]Ga-DOTATATE PET/CT,B组40例比较[18F]AlF-NOTA-LM3与[68Ga]Ga-NODAGA-LM3 PET/CT;[18F]AlF-NOTA-LM3腹部器官摄取更低,肝及淋巴结病灶检出数和病灶水平灵敏度更高,并改变了部分患者的临床管理。
要点
- [18F]AlF-NOTA-LM3腹部器官摄取低于[68Ga]Ga-DOTATATE和[68Ga]Ga-NODAGA-LM3。
- [18F]AlF-NOTA-LM3肝病灶检出数684 vs [68Ga]Ga-DOTATATE 449(P<0.001),淋巴结病灶41 vs 29(P=0.005)。
- [18F]AlF-NOTA-LM3病灶水平灵敏度高于[68Ga]Ga-DOTATATE(90.6% vs 67.6%,P<0.001)和[68Ga]Ga-NODAGA-LM3(90.9% vs 81.0%,P<0.001)。
核心结论
- [18F]AlF-NOTA-LM3诊断效能优于[68Ga]Ga-DOTATATE和[68Ga]Ga-NODAGA-LM3,并在部分患者中显示出指导临床决策的显著价值。
研究设计与样本
- 前瞻性随机对照研究,纳入组织学确诊的高分化神经内分泌肿瘤患者78例。
- A组38例接受[18F]AlF-NOTA-LM3与[68Ga]Ga-DOTATATE PET/CT,B组40例接受[18F]AlF-NOTA-LM3与[68Ga]Ga-NODAGA-LM3 PET/CT。
- 比较生物分布、病灶数量和病灶摄取,评估对临床管理的影响,并对[18F]AlF-NOTA-LM3与68Ga标记示踪剂的灵敏度进行事后分析。
- 临床试验注册号:NCT06056362。
主要发现
- [18F]AlF-NOTA-LM3腹部器官摄取低于[68Ga]Ga-DOTATATE和[68Ga]Ga-NODAGA-LM3。
- [18F]AlF-NOTA-LM3肝病灶检出数684 vs [68Ga]Ga-DOTATATE 449(P<0.001),淋巴结病灶41 vs 29(P=0.005)。
- [18F]AlF-NOTA-LM3肝病灶检出数625 vs [68Ga]Ga-NODAGA-LM3 490(P=0.001)。
- [18F]AlF-NOTA-LM3病灶水平灵敏度显著高于[68Ga]Ga-DOTATATE(90.6% vs 67.6%,P<0.001)和[68Ga]Ga-NODAGA-LM3(90.9% vs 81.0%,P<0.001),尤其对肝转移灶。
- [18F]AlF-NOTA-LM3导致A组18.5%(7/38)和B组12.5%(5/40)患者临床管理改变;A组主要改变13.2%(5/38)、次要改变5.3%(2/38),B组主要改变7.5%(3/40)、次要改变5%(2/40)。
关键数值与推荐
- A组[18F]AlF-NOTA-LM3 vs [68Ga]Ga-DOTATATE:肝病灶684 vs 449(P<0.001),淋巴结病灶41 vs 29(P=0.005)。
- B组[18F]AlF-NOTA-LM3 vs [68Ga]Ga-NODAGA-LM3:肝病灶625 vs 490(P=0.001)。
- 病灶水平灵敏度:[18F]AlF-NOTA-LM3 90.6% vs [68Ga]Ga-DOTATATE 67.6%(P<0.001);[18F]AlF-NOTA-LM3 90.9% vs [68Ga]Ga-NODAGA-LM3 81.0%(P<0.001)。
- 临床管理改变:A组18.5%(7/38)vs B组12.5%(5/40);主要改变A组13.2%(5/38)vs B组7.5%(3/40);次要改变A组5.3%(2/38)vs B组5%(2/40)。
临床怎么用
- 原文结论指出[18F]AlF-NOTA-LM3诊断效能优于[68Ga]Ga-DOTATATE和[68Ga]Ga-NODAGA-LM3。
- 原文结论指出[18F]AlF-NOTA-LM3在部分患者中显示出指导临床决策的显著价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to compare the diagnostic efficacy and clinical management impact of [18F]AlF-NOTA-LM3 with [68Ga]Ga-DOTATATE or [68Ga]Ga-NODAGA-LM3 in patients with well-differentiated neuroendocrine tumors. METHODS: Patients with histologically confirmed well-differentiated NETs were prospectively recruited and randomized into two arms: Arm A, undergo [18F]AlF-NOTA-LM3 and [68Ga]Ga-DOTATATE PET/CT; Arm B, undergo [18F]AlF-NOTA-LM3 and [68Ga]Ga-NODAGA-LM3 PET/CT. Biodistribution, lesion numbers, and lesion uptake were compared. The impact on clinical management was evaluated. Additionally, a post-hoc analysis of the sensitivity of [18F]AlF-NOTA-LM3 and 68Ga-labeled tracers was evaluated. RESULTS: A total of 78 patients were included in this study: 38 in Arm A and 40 in Arm B. [18F]AlF-NOTA-LM3 showed lower abdominal organ uptake than [68Ga]Ga-DOTATATE and [68Ga]Ga-NODAGA-LM3. [18F]AlF-NOTA-LM3 was superior to [68Ga]Ga-DOTATATE in liver (684 vs. 449, P<0.001) and lymph node lesion (41 vs. 29, P = 0.005) detection, and superior to [68Ga]Ga-NODAGA-LM3 in liver lesion (625 vs. 490, P = 0.001) detection. The lesion-level sensitivity of [18F]AlF-NOTA-LM3 was significantly higher than that of [68Ga]Ga-DOTATATE (90.6% vs. 67.6%, P<0.001) and [68Ga]Ga-NODAGA-LM3 (90.9% vs. 81.0%, P<0.001), particularly for liver metastases. [18F]AlF-NOTA-LM3 led to a clinical management change in 18.5% (7/38) of patients in Arm A and 12.5% (5/40) of patients in Arm B: 13.2% (5/38) in Arm A and 7.5% (3/40) in Arm B with major changes, while 5.3% (2/38) in Arm A and 5% (2/40) in Arm B with minor changes. CONCLUSION: [18F]AlF-NOTA-LM3 shows superior diagnostic efficacy than [68Ga]Ga-DOTATATE and [68Ga]Ga-NODAGA-LM3. [18F]AlF-NOTA-LM3 demonstrates significant value in guiding clinical decision-making in a subgroup of patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT06056362.
引用
- Liu M, Zhang Y, Yan X, et al. Assessment of the diagnostic efficacy and clinical significance of [18F]AlF-NOTA-LM3 PET/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2025. PMID: 40762797. doi:10.1007/s00259-025-07484-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。